News | July 06, 2022
CEPI and Codiak BioSciences partner to develop protective Betacoronavirus vaccine
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
As per partnership, Carbanio will arrange raw materials and other custom chemicals for Proexp Pharma Pvt. Ltd. through an uninterrupted digital process of the company
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Subscribe To Our Newsletter & Stay Updated
